Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (the "Company") on February 4, 2020, reporting events occurring on February 3, 2020. The Company, incorporated in Delaware, operates primarily through its interest in Rafael Pharmaceuticals, Inc. ("Rafael Pharma").
Key Financial Metrics and Transaction Details
The filing discloses a new financing arrangement rather than standard periodic financial results. Key metrics related to the transaction include:
- Facility Size: A revolving line of credit of up to $50,000,000.
- Purpose: Funding clinical trials and other capital needs for Rafael Pharma.
- Interest Rate: Mid-term Applicable Federal Rate (AFR) published by the IRS.
- Maturity: February 3, 2025, or earlier upon a change of control or sale of Rafael Pharma.
- Ownership Structure: The Company owns an effective 38.7% interest in Rafael Pharma and 37.5% of the equity in the lender, RP Finance, LLC.
Material Changes and Transaction Terms
The primary material event is the execution of the Line of Credit Loan Agreement between Rafael Pharma and RP Finance, LLC. Material terms include:
- Funding Obligation: The Company and its Chairman/CEO, Howard Jonas, each own 37.5% of RP Finance and are required to fund 37.5% of any funding requests from Rafael Pharma.
- Equity Issuance: Rafael Pharma agreed to issue 12% of its common stock to RP Finance as part of the agreement, subject to anti-dilution protection.
- Repayment: Borrowed funds must be prepaid using proceeds from equity sales by Rafael Pharma.
- Drawdown Notice: Rafael Pharma may draw on the facility with 60 days' notice.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking financial guidance, revenue projections, or general management commentary regarding the Company's overall outlook. The transaction is structured to support Rafael Pharma's clinical trial operations. A key contingency is the requirement for equity sales by Rafael Pharma to repay the loan, and the facility's maturity is accelerated by a change of control or asset sale.
Investor Verification Checklist
- Verify the Company's effective 38.7% ownership interest in Rafael Pharma and the implications of the 12% equity issuance to RP Finance.
- Confirm the specific funding obligations of the Company and Howard Jonas regarding the 37.5% share of the $50 million facility.
- Assess the liquidity risk associated with the requirement to prepay the loan solely from Rafael Pharma's equity sale proceeds.
- Review the anti-dilution protections granted to RP Finance in the Line of Credit Agreement.